We serve Chemical Name:5-Hydroxy-1-(4-sulfophenyl)pyrazole-3-carboxylic acid CAS:21951-33-7 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:5-Hydroxy-1-(4-sulfophenyl)pyrazole-3-carboxylic acid
CAS.NO:21951-33-7
Synonyms:EINECS 244-677-2
Molecular Formula:C10H8N2O6S
Molecular Weight:284.24
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:
Exact Mass:
LogP:
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like EINECS 244-677-2 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,EINECS 244-677-2 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,EINECS 244-677-2 Use and application,EINECS 244-677-2 technical grade,usp/ep/jp grade.
Related News: Due to the time-consuming process of EIA approval and EIA acceptance for newly-built projects, and environmental protection supervision policies are becoming increasingly tight, the company strives to improve capacity utilization through reasonable equipment layout when designing and constructing capacity. 5-Hydroxy-1-(4-sulfophenyl)pyrazole-3-carboxylic acid manufacturer Due to the time-consuming process of EIA approval and EIA acceptance for newly-built projects, and environmental protection supervision policies are becoming increasingly tight, the company strives to improve capacity utilization through reasonable equipment layout when designing and constructing capacity. 5-Hydroxy-1-(4-sulfophenyl)pyrazole-3-carboxylic acid supplier Australia’s ban followed an earlier move by the US Friday to deny entry to foreign nationals who have traveled in China in the last 14 days. 5-Hydroxy-1-(4-sulfophenyl)pyrazole-3-carboxylic acid vendor One key question for the fixed-duration combo is whether it can sustain remission after treatment has stopped. In the preliminary analysis of the GLOW trial, at three months after treatment ended, 51.9% of the Imbruvica-Venclexta patients had undetectable measurable residual disease (uMRD)—a stringent marker reflecting no signs of cancer—in bone marrow, versus 17.1% for the control group. The rates for peripheral blood were 54.7% and 39% for the two groups, respectively. 5-Hydroxy-1-(4-sulfophenyl)pyrazole-3-carboxylic acid factory Any US citizen who has been in the Hubei province in the last 14 days will be subject to up to 14 days of mandatory quarantine upon return to the United States.